Kinetics of T-cell-based assays on cerebrospinal fluid and peripheral blood mononuclear cells in patients with tuberculous meningitis

Ki-Ho Park¹, Mi Suk Lee¹, Sang-Oh Lee², Sang-Ho Choi², Yang Soo Kim², Jun Hee Woo², Joong Koo Kang³, Sang-Ahm Lee³, and Sung-Han Kim²

Background/Aims: The goal of this study was to monitor tuberculosis (TB)-specific T-cell responses in cerebrospinal fluid-mononuclear cells (CSF-MCs) and peripheral blood mononuclear cells (PBMCs) in patients with tuberculous meningitis (TBM) over the course of anti-TB therapy.

Methods: Adult patients (≥16 years) with TBM admitted to Asan Medical Center, Seoul, South Korea, were prospectively enrolled between April 2008 and April 2011. Serial blood or CSF samples were collected over the course of the anti-TB therapy, and analyzed using an enzyme-linked immunosorbent spot (ELISPOT) assay.

Results: Serial ELISPOT assays were performed on PBMCs from 17 patients (seven definite, four probable, and six possible TBM) and CSF-MCs from nine patients (all definite TBM). The median number of interferon-gamma (IFN-γ)-producing T-cells steadily increased during the first 6 months after commencement of anti-TB therapy in PBMCs. Serial CSF-MC ELISPOT assays revealed significant variability in immune responses during the first 6 weeks of anti-TB therapy, though early increases in CSF-MC ELISPOT results were associated with treatment failure or paradoxical response.

Conclusions: Serial analysis of PBMCs by ELISPOT during the course of treatment was ineffective for predicting clinical response. However, increases in TB-specific IFN-γ-producing T-cells in CSF-MCs during the early phase of anti-TB therapy may be predictive of clinical failure.

Keywords: Tuberculosis; Meningitis; Enzyme-linked immunosorbent assay; Cerebrospinal fluid

INTRODUCTION

Mycobacterium tuberculosis-specific interferon-γ (IFN-γ) releasing assays (IGRAs) are an effective method for diagnosing tuberculous meningitis (TBM) in both peripheral blood mononuclear cells (PBMC) and cerebrospinal fluid mononuclear cells (CSF-MC) [1-4]. Serial analysis of tuberculosis (TB)-specific IFN-γ-producing T-cell responses by IGRA over the course of anti-TB therapy may be useful in predicting clinical response [5-9]; however, it is uncertain whether such an analysis would be beneficial in patients with TBM. Here, we evaluated TB-specific T-cell responses in CSF-MC and PBMCs using an enzyme-linked immunosorbent
spot (ELISPOT) assay in patients with TBM during the course of anti-TB therapy.

METHODS

Study design and patients
Adult patients (≥ 16 years) with suspected TBM admitted to Asan Medical Center, a 2,700-bed tertiary hospital in Seoul, South Korea, were prospectively enrolled between April 2008 and April 2011. Patients with suspected TBM were categorized as definite, probable, or possible TBM, according to a recently proposed uniform case definition, with some modifications [10]. In brief, patients were classified as having “definite TBM” if clinical specimens were found to be positive for *M. tuberculosis* either by culture or through the use of an *M. tuberculosis* polymerase chain reaction assay. Patients were classified as having “probable TBM” or “possible TBM” according to the diagnostic scoring system [10]. All patients received standard TB therapy in accordance with the recommendations of the American Thoracic Society [11]. Only patients willing to provide serial blood or CSF samples over the course of anti-TB therapy were included in the final analysis. The study protocol was approved by the Institutional Review Board of Asan Medical Center.

ELISPOT assay
PBMCs and CSF-MCs were isolated from peripheral venous blood (~8 mL) and CSF (~4 mL), respectively, within 30 minutes of collection. Cells were then resuspended in appropriate medium, and analyzed using an ELISPOT assay (T-SPOT.TB, Oxford Immunotec, Oxford, UK) as described previously [1,12]. The minimum threshold for a positive response was defined as ≥ 6 spot-forming cells per well (SFCs) after subtraction of the negative control. Indeterminate responses were defined as < 20 spots in the positive control well, or > 10 spots in the negative control well [1,12].

RESULTS

Forty-six patients with TBM were prospectively enrolled during the study period. Of these 46 patients, 17 (37%), 8 (17%), and 21 (46%) were classified as having definite, probable, and possible TBM, respectively. Baseline ELISPOT assays were performed on PBMCs and CSF-MCs from all 46 patients; however, only 22 of these patients were willing to provide serial samples over the course of their treatment. Baseline clinical characteristics were similar between patients providing serial samples and those providing only pretreatment samples (Table 1).

Serial PBMC ELISPOT assays were performed on 17 patients (seven definite, four probable, and six possible TBM). Among the 15 patients exhibiting positive ELISPOT results at baseline, no negative reversions (< 6 spots) were observed during the course of treatment; positive conversion (≥ 6 spots) occurred in one of two patients initially diagnosed as negative by ELISPOT. Median IFN-γ-producing T-cell numbers steadily increased during the first 6 months after commencement of anti-TB therapy in these patients (Fig. 1).

Serial CSF-MC ELISPOT assays were performed on nine patients with TBM (all definite TBM). Serial changes in the number of IFN-γ-producing T-cells were associated with both white blood cell (WBC) counts and clinical responses (Fig. 2). IFN-γ-producing T-cell counts decreased in four patients with decreasing CSF WBC counts (patients 1 to 4), but increased in four others exhibiting increased CSF WBC counts (patients 6 to 9); one patient (patient 5) exhibited no change in IFN-γ-producing T-cell numbers despite a decrease in CSF WBC counts. None of the five patients, in whom IFN-γ-producing T-cells decreased or remained constant during the early phase of anti-TB therapy, experienced a worsening of clinical symptoms; however, all four patients with definite TBM, in whom IFN-γ-producing T-cells increased, exhibited clear signs of clinical deterioration.

DISCUSSION

Analyses of serial TB-specific IFN-γ-producing T-cell responses in CSF-MCs and PBMCs of patients with TBM remain limited. Here, we showed that TB-specific IFN-γ-producing T-cell responses in PBMC increased steadily over the course of 6 months after initiation of anti-TB therapy. This finding is consistent with a previ-
Park KH, et al. Serial ELISPOT assays for TB meningitis

Table 1. Baseline clinical characteristics of 46 patients with tuberculosis meningitis

| Characteristic                              | Patients undergoing serial ELISPOT assay (n = 22) | Patients not undergoing serial ELISPOT assay (n = 24) |
|---------------------------------------------|--------------------------------------------------|---------------------------------------------------|
| Age, yr                                     | 45.7 ± 12.4                                      | 47.0 ± 16.2                                       |
| Male sex                                    | 10 (46)                                          | 11 (46)                                          |
| Underlying condition                        |                                                  |                                                  |
| Diabetes                                    | 1 (5)                                            | 5 (21)                                           |
| Chronic renal failure                       | 1 (5)                                            | 0                                                 |
| Rheumatism                                  | 2 (9)                                            | 0                                                 |
| Malignancy                                  | 1 (5)                                            | 0                                                 |
| Liver cirrhosis                             | 0                                                | 0                                                 |
| Transplantation                             | 0                                                | 0                                                 |
| No underlying illness                       | 18 (82)                                          | 19 (79)                                          |
| Immunosuppression a                         | 3 (14)                                           | 1 (4)                                            |
| Prior TB treatment                          | 3 (14)                                           | 1 (4)                                            |
| Tuberculin skin test (after 48 hr)          |                                                  |                                                  |
| Induration ≥ 5 mm                           | 6/21 (29)                                        | 5/21 (24)                                        |
| Induration ≥ 10 mm                          | 5/21 (24)                                        | 5/21 (24)                                        |
| ELISPOT assay before the anti-TB treatment  |                                                  |                                                  |
| Positive ELISPOT results on PBMC           | 19 (86)                                          | 17 (71)                                          |
| Positive ELISPOT results on CSF-MC          | 17 (77)                                          | 14 (58)                                          |
| CSF profile                                 |                                                  |                                                  |
| WBC count, median cells × 10^6/L            | 150 (50–220)                                     | 160 (83–510)                                     |
| % Lymphocytes                               | 70 (43–81)                                       | 81 (59–88)                                       |
| % Neutrophils                               | 15 (0–45)                                        | 1 (0–23)                                         |
| Protein, mg/L                               | 184 (114–325)                                    | 190 (103–316)                                    |
| Glucose, g/dL                               | 47 (34–61)                                       | 45 (37–59)                                       |
| CSF/serum glucose ratio                     | 0.37 (0.23–0.50)                                 | 0.40 (0.31–0.46)                                 |
| CSF adenosine deaminase, U/L                | 10.5 (6.8–17.1)                                  | 8.1 (5.1–14.3)                                   |
| Positive AFB stain                          | 2 (9)                                            | 1 (4)                                            |
| Positive M. tuberculosis PCR                | 8 (36)                                           | 4 (17)                                           |
| Positive M. tuberculosis culture            | 12 (55)                                          | 4 (17)                                           |

Values are presented as mean ± SD, number (%), or median (interquartile range).

ELISPOT, enzyme-linked immunosorbent spot; TB, tuberculosis; PBMC, peripheral blood mononuclear cells; CSF-MC, cerebrospinal fluid-mononuclear cells; WBC, white blood cell; AFB, acid fast bacilli; M. tuberculosis, Mycobacterium tuberculosis; PCR, polymerase chain reaction.

aTuberculosis meningitis (TBM) included cases of definite (n = 17), probable (n = 8), and possible (n = 21) TB. Of the 46 patients with TBM, 10 (22%) had miliary TB at initial presentation.
bImmunosuppression was defined as an underlying disease such as rheumatism, liver cirrhosis, or chronic renal failure, and/or patients receiving immunosuppressive therapy.

ous ELISPOT analysis performed by our laboratory in which median TB-specific T-cell responses were shown to increase steadily for up to 6 months in 52 patients with extrapulmonary TB, followed by a decrease thereafter [13]. A more complete comparison was not possible however, as long-term follow-up (> 6 months) in patients with TBM was not performed.

While some studies have reported increased T-cell
responses during or after anti-TB therapy [13-17], consistent associations between anti-TB therapy and an attenuated T-cell response in PBMCs have also been observed [5-9,18-20]. The reasons underlying this discrepancy, along with the small number of negative reversions with increased T-cell responses described in this study are not clear. One possible explanation may be that extrapulmonary TB is more likely to exhibit a paradoxical response to anti-TB therapy [21]. Most studies examining IGRA kinetics during anti-TB therapy have focused exclusively on pulmonary TB [5,6,8,15-17,19,20], which may explain some of the different response kinetics observed in our studies. Further studies will be necessary to evaluate differences in immune response kinetics between pulmonary and extrapulmonary TB.

In addition to PBMC-related effects, we also observed increased TB-specific T-cell responses in CSF-MC during the early phase of anti-TB treatment, which were associated with clinical deterioration in patients with definite TBM. Previously, we had reported a case of TBM in which a therapy-induced increase in TB-specific T-cell responses in CSF-MC and PBMCs occurred [22]. Taken together, these studies suggest that the clinical deterioration seen during the early phase of TB therapy may be the result of TB-specific T-cell responses. Interestingly, these heightened T-cell responses occurred not only in patients who died as a result of TBM but also in those who experienced clinical deterioration despite CSF sterilization, but ultimately improved without modification to their anti-TB regimen (i.e., paradoxical response). These observations are consistent with our earlier work showing that an “immunologic paradox” often preceded a “therapeutic paradox,” which is strongly predictive of poor outcomes [22]. Further studies will be needed to evaluate the prognostic value of increased TB-specific T-cell responses during anti-TB therapy, and the clinical utility of this phenomenon in patients with TBM.

Like all studies, this work is not without limitations. Ten of the seventeen patients (59%) in whom serial PBMC ELISPOT assays were performed were classified as having probable or possible TBM on the basis of clinical features and image findings alone, in the absence of microbiological confirmation. However, as existing bacteriological methods are not sufficiently sensitive to be used for diagnosing TBM alone, the majority of studies include patients based upon a combination of microbiological, clinical, and radiological criteria [1,23,24]. These patients were subsequently
serial ELISPOT assays for TB meningitis

Figure 2. Serial cerebrospinal fluid-mononuclear cell (CSF-MC) enzyme-linked immunosorbent spot assays after initiation of anti-tuberculosis (TB) therapy in nine patients with definite tuberculous meningitis. Note that the CSF white blood cell (WBC) counts on the X-axis decrease from left to right in patients 1 to 5 but increase in patients 6 to 9. Of the four patients (patients 6 to 9) in whom interferon-γ (IFN-γ) producing T-cells increased, two (patients 6 and 9) died despite anti-TB therapy, while the other two (patients 7 and 8) experienced paradoxical responses. ESAT-6, early secreting antigenic target-6; CFP-10, culture filtrate protein-10.

classified using a recently proposed uniform case definition as a way to minimize selection bias [10]. Second, serial ELISPOT assays were performed in only a small number of patients with TBM. Although a clear trend towards increased T-cell responses in PBMCs was observed during the anti-TB therapy, the small sample size was insufficient for most statistical analyses. Finally, CSF-MC ELISPOT assays were not performed...
at regular intervals. Further studies should include a larger number of patients with serial measurement performed at regular intervals.

Despite these limitations, this study may be useful for understanding the immunologic response to anti-TB therapy in patients with TBM. Serial analysis of PBMCs by ELISPOT during the course of treatment was found to be ineffective for predicting clinical response; however, increases in TB-specific IFN-γ-producing T-cells in CSF-MC during the early phase of anti-TB therapy may be predictive of clinical failure.

KEY MESSAGE

1. Serial peripheral blood mononuclear cell enzyme-linked immunosorbent spot assays during the course of treatment were found to be ineffective for predicting clinical response in patients with tuberculous meningitis (TBM).
2. Increases in tuberculosis (TB)-specific interferon-gamma producing T-cell response on cerebrospinal fluid-mononuclear cells during the early phase of anti-TB therapy may be predictive of clinical failure in patients with TBM.

Conflict of interest
No potential conflict of interest relevant to this article was reported.

Acknowledgments
This study was supported by the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (grant number: 2011-A110004).

REFERENCES

1. Kim SH, Cho OH, Park SJ, et al. Rapid diagnosis of tuberculous meningitis by T cell-based assays on peripheral blood and cerebrospinal fluid mononuclear cells. Clin Infect Dis 2010;50:1349-1358.
2. Patel VB, Singh R, Connolly C, et al. Cerebrospinal T-cell responses aid in the diagnosis of tuberculous meningitis in a human immunodeficiency virus- and tuberculosis-endemic population. Am J Respir Crit Care Med 2010;182:569-577.
3. Kim SH, Chu K, Choi SJ, et al. Diagnosis of central nervous system tuberculosis by T-cell-based assays on peripheral blood and cerebrospinal fluid mononuclear cells. Clin Vaccine Immunol 2008;15:1356-1362.
4. Thomas MM, Hinks TS, Raghuraman S, et al. Rapid diagnosis of Mycobacterium tuberculosis meningitis by enumeration of cerebrospinal fluid antigen-specific T-cells. Int J Tuberc Lung Dis 2008;12:651-657.
5. Carrara S, Vincenti D, Petrosillo N, Amicosante M, Girardi E, Goletti D. Use of a T cell-based assay for monitoring efficacy of antituberculosis therapy. Clin Infect Dis 2004;38:754-756.
6. Aiken AM, Hill PC, Fox A, et al. Reversion of the ELISPOT test after treatment in Gambian tuberculosis cases. BMC Infect Dis 2006;6:66.
7. Kobashi Y, Mouri K, Yagi S, Obase Y, Miyashita N, Oka M. Transition changes in T-cell responses to Mycobacterium tuberculosis-specific antigens during treatment. J Infect 2009;53:197-204.
8. Katiriar SK, Sampath A, Bihari S, Mamtani M, Kulkarni H. Use of the QuantiFERON-TB Gold In-Tube test to monitor treatment efficacy in active pulmonary tuberculosis. Int J Tuberc Lung Dis 2008;12:1146-1152.
9. Dheda K, Pooran A, Pai M, et al. Interpretation of Mycobacterium tuberculosis antigen-specific IFN-gamma release assays (T-SPOT.TB) and factors that may modulate test results. J Infect 2007;55:169-173.
10. Marais S, Thwaites G, Schoeman JF, et al. Tuberculous meningitis: a uniform case definition for use in clinical research. Lancet Infect Dis 2010;10:583-582.
11. Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603-662.
12. Kim SH, Choi SJ, Kim HB, Kim NJ, Oh MD, Choe KW. Diagnostic usefulness of a T-cell based assay for extrapulmonary tuberculosis. Arch Intern Med 2007;167:2255-2259.
13. Park KH, Cho OH, Ko GB, et al. Serial testing of T-SPOT. TB assays with anti-tuberculosis therapy in patients with extrapulmonary tuberculosis. Infect Chemother 2011;43:245-250.
14. Vekemans J, Lienhardt C, Sillah JS, et al. Tuberculosis contacts but not patients have higher gamma interferon
responses to ESAT-6 than do community controls in The Gambia. Infect Immun 2001;69:6554-6557.
15. Ulrichs T, Anding R, Kaufmann SH, Munk ME. Numbers of IFN-gamma-producing cells against ESAT-6 increase in tuberculosis patients during chemotherapy. Int J Tuberc Lung Dis 2006;10:1181-1183.
16. Ferrand RA, Bothamley GH, Whelan A, Dockrell HM. Interferon-gamma responses to ESAT-6 in tuberculosis patients early into and after anti-tuberculosis treatment. Int J Tuberc Lung Dis 2005;9:1034-1039.
17. Al-Attiyah R, Mustafa AS, Abal AT, Madi NM, Andersen P. Restoration of mycobacterial antigen-induced proliferation and interferon-gamma responses in peripheral blood mononuclear cells of tuberculosis patients upon effective chemotherapy. FEMS Immunol Med Microbiol 2003;38:249-256.
18. Pathan AA, Wilkinson KA, Kleereman P, et al. Direct ex vivo analysis of antigen-specific IFN-gamma-secreting CD4 T cells in Mycobacterium tuberculosis-infected individuals: associations with clinical disease state and effect of treatment. J Immunol 2001;167:5217-5225.
19. Lee SW, Lee CT, Yim JJ. Serial interferon-gamma release assays during treatment of active tuberculosis in young adults. BMC Infect Dis 2010;10:300.
20. Chee CB, KhinMar KW, Gan SH, et al. Tuberculosis treatment effect on T-cell interferon-gamma responses to Mycobacterium tuberculosis-specific antigens. Eur Respir J 2010;36:355-361.
21. Cheng VC, Yam WC, Woo PC, et al. Risk factors for development of paradoxical response during antituberculosis therapy in HIV-negative patients. Eur J Clin Microbiol Infect Dis 2003;22:597-602.
22. Kim SH, Kim YS. Immunologic paradox in the diagnosis of tuberculous meningitis. Clin Vaccine Immunol 2009;16:1847-1849.
23. Thwaites GE, Chau TT, Stepniewska K, et al. Diagnosis of adult tuberculous meningitis by use of clinical and laboratory features. Lancet 2002;360:1287-1292.
24. Thwaites GE, Nguyen DB, Nguyen HD, et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med 2004;351:1741-1751.